<DOC>
	<DOCNO>NCT03038230</DOCNO>
	<brief_summary>This First-in-Human , single arm , open-label , multi-national study design determine safety , tolerability preliminary efficacy MCLA 117 .</brief_summary>
	<brief_title>MCLA-117 Acute Myelogenous Leukemia</brief_title>
	<detailed_description>Study Design : This open label , single arm , multinational , first-in-human study consist 2 part . Part 1 consist dose escalation cohort Part 2 dose expansion cohort . The study population include adult AML patient ( subtypes AML ) relapse refractory disease newly diagnose elderly untreated AML patient . In Part 1 , dose escalation cohort follow dose-limiting toxicity ( DLT ) maximum tolerate dose ( MTD ) RecommendedPart2Dose ( RP2D ) define . Dose escalation decision make Data Review Committee primarily guide safety data observe end Cycle 1 , well on-going assessment safety beyond Cycle 1 later cohort . Part 2 begin MTD RP2D determine Part 1 . Part 2 characterize safety , tolerability , Pharmacokinetic ( PK ) , Pharmacodynamic ( PD ) , immunogenicity ass preliminary efficacy MCLA-117 . This part enroll least 15 evaluable patient ( define evaluable first efficacy assessment ) . For part , study consist 3 period : Screening period ( 28 day prior first dose study drug ) ; Treatment period ( first dose study drug last dose study drug treatment cycle 28 day ) ; Follow Up period ( 30 day last dose quarterly check survival data 1 year ) . Participants ' safety monitor throughout study . Patients permit receive MCLA-117 beyond Cycle 1 condition allow . Number Sites : Approximately 7 center five country estimate involved Parts 1 2 study . Additional site may add ensure acceptable enrollment rate replace non-enrolling/withdrawn site .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Bispecific</mesh_term>
	<criteria>1 . Male female age ≥18 year old ; 2 . Signed informed consent form 3 . AML either de novo secondary either : 1. relapse follow initial response 1 prior salvage therapy 2. fail primary induction therapy complete remission approve therapy available , 1 prior salvage therapy 3. newly diagnose untreated AML patient ≥ 65 year age , candidate standard available induction chemotherapy 4 . Screening CLEC12A level ≥ 20 % ; 6 . Estimated life expectancy least 8 week ; 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 ; 8 . Significant toxicity incur result previous anticancer therapy resolve ≤ Grade 1 ( NCICTCAE version 4.03 ) ; 9 . Acceptable laboratory value screen ; 10 . Male patient must agree use adequate medically accept method contraception throughout study least 3 month sexual partner woman child bear potential ( WOCBP ) . 11 . WOCBP must use highly effective medically accept method contraception avoid pregnancy throughout study least 3 month study ; 12 . WOCBP must negative serum urine pregnancy test within 72 hour prior start study drug . 1 . Diagnosis chronic myelogenous leukemia blast crisis ; 2 . Less 3 month since receive hematopoietic stem cell transplantation , autologous allogeneic and/or clinically significant graft versushost disease require treatment time screen and/or patient history severe graft versushost disease ; 3 . Cancer chemotherapy within four week prior start MCLA117 ; 4 . Previous treatment radiotherapy , immunotherapeutic agent , receipt live vaccine 4 week prior study drug administration ; 5 . Previous treatment investigational agent within 4 week prior MCLA117 administration ; 6 . Concurrent need use corticosteroid &gt; 10 mg/day oral prednisone equivalent , except topical preparation ( e.g. , topical cream , steroid inhaler , nasal spray ophthalmic solution ) ; 7 . Use immunosuppressant medication within 4 week MCLA117 administration ; 8 . Clinically active central nervous system ( CNS ) leukemia ; 9 . Patients pregnant lactating ; 10 . Patients active infection unexplained fever screen first schedule day dose ; 11 . Patients know hypersensitivity component MCLA117 prior hypersensitivity reaction human humanize monoclonal antibody ; 12 . Patients know HIV , hepatitis B C ; 13 . Patients New York Heart Association Class III IV congestive heart failure leave ventricular ejection fraction ( LVEF ) &lt; 50 % , significant uncontrolled cardiac disease , current diagnosis unstable angina , uncontrolled congestive heart failure , new myocardial infarction , ventricular arrhythmia require medication ; 14 . Prior malignancy ( basal cell carcinoma cervical situ carcinoma ) unless treat curative intend without evidence malignant disease 1 year screening . Patients prior hematologic malignancy progress AML ( Myelodysplastic syndrome , myeloproliferative neoplasm , biphenotypic leukemia , AcuteLymphocyticLeukemia ) AML relapse eligible ; 15 . Urinary protein &gt; 2+ possibly indicative renal disease . If 24 hour urine protein show result &lt; 100 mg protein , subject eligible ; 16 . Patients medical psychological condition deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result ; 17 . WOCBP males WOCB partner willing use highly effective medically accept method contraception 90 day last study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>human bispecific full length IgG antibody , CLEC12A , CD3</keyword>
	<keyword>MCLA-117</keyword>
	<keyword>First Human</keyword>
	<keyword>Antibodies , Bispecific</keyword>
	<keyword>Immunologic Factors</keyword>
	<keyword>relapse , refractory patient</keyword>
	<keyword>AML , minimal residual disease ( MRD )</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>CD34+CD38</keyword>
	<keyword>T-cell recruiting</keyword>
</DOC>